Acute kidney injury is major complication after open heart surgery. The cause of acute kidney injury following open heart surgery is related to activation of sympathetic nervous system, decrease of renal blood flow, ischemia-reperfusion injury and systemic inflammatory response. Infective endocarditis patients undergoing open heart surgery have systemic inflammatory response associated with infective endocarditis. And the inflammatory response can be aggravated by cardiopulmonary bypass. The incidence of acute kidney injury following open heart surgery due to infective endocarditis was 50% in a previous report. And this acute kidney injury was related to the poor outcome and high mortality. Thus, the preventive method to protect kidney function will be needed in the patients with infective endocarditis undergoing open heart surgery. Dexmedetomidine is a selective α2-agonist and has sedative, analgesic, and CNS depressive effect. And several experimental study demonstrated the renal protective effect. Intraoperative dexmedetomidine administration can reduce the amount of anesthetics needed and suppress the sympathetic response resulted by surgical stimulation. And dexmedetomidine was reported to reduce the level of serum cortisol, epinephrine and norepinephrine during the operation. Thus, these effects of dexmedetomidine can be expected to reduce the incidence of acute kidney injury. Therefore, the investigators hypothesized that dexmedetomidine has renal protective effect and this effect might be related to the suppression of inflammatory response. Thus, the investigators will evaluate the incidence of acute kidney injury and the incidence of major adverse kidney events (MAKE) after open heart surgery due to infective endocarditis and the level of inflammatory mediators. The primary end point of this study is the incidence of acute kidney injury after open heart surgery due to infective endocarditis. And secondary end point is the incidence of MAKE, the level of cystatin C which is related to the renal function, the level of inflammatory mediator and the postoperative morbidities.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
94
Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, South Korea
RECRUITINGThe incidence of acute kidney injury
Time frame: 1 week
Cystatin C level
serum cystatin C level (mg/L)
Time frame: postoperative day 1,2,3 and 5
inflammatory mediator(IL-6) level
serum inflammatory mediator (IL-6(pg/mL)
Time frame: postoperative day 1,2,3 and 5
inflammatory mediator(CRP) level
serum inflammatory mediator (CRP(mg/L))
Time frame: postoperative day 1,2,3 and 5
inflammatory mediator(WBC) level
Serum WBC(/microL) level
Time frame: postoperative day 1,2,3 and 5
inflammatory mediator(neutrophil count) level
serum inflammatory mediator (neutrophil count(/microL)) level
Time frame: postoperative day 1,2,3 and 5
serum norepinephrine/epinephrine level(ng/mL)
Time frame: postoperative day 1,2,3 and 5
intraoperative hemodynamics measured by amount of used vasopressors(mL)
Time frame: postoperative day 1,2,3 and 5
intraoperative fluid intake and output
intraoperative intake and output measured by the amount of fluid(crystalloid/colloid)(mL) and blood administered(mL)
Time frame: postoperative day 1,2,3 and 5
postoperative complications
postoperative complications such as development of myocardial infarction, arrhythmia, cerebrovascular accident, wound infection, and mortality.
Time frame: postoperative day 1,2,3 and 5
Major adverse kidney events (MAKE)
Time frame: 3month, 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.